Octant

Los Angeles, United States Founded: 2017 • Age: 9 yrs
Human cell interaction platform is provided for drug discovery.
Request Access

About Octant

Octant is a company based in Los Angeles (United States) founded in 2017. It operates as a HealthTech. Octant has raised $110 million across 4 funding rounds from investors including HHS, Allen & Company and Bristol-Myers Squibb. The company has 63 employees as of December 31, 2024. Octant offers products and services including OCT-980 and Genetic Disease Correctors. Octant operates in a competitive market with competitors including DNAnexus, Arbor Biotechnologies, Cytel, Verge Genomics and Singleron, among others.

  • Headquarter Los Angeles, United States
  • Employees 63 as on 31 Dec, 2024
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Octant, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $110 M (USD)

    in 4 rounds

  • Latest Funding Round
    $80 M (USD), Series B

    Apr 21, 2022

  • Investors
    HHS

    & 7 more

  • Employee Count
    63

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Octant

Octant offers a comprehensive portfolio of products and services, including OCT-980 and Genetic Disease Correctors. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Designed to correct protein misfolding in retinal disorders.

Developed to address protein misfolding in genetic diseases.

People of Octant
Headcount 50-200
Employee Profiles 38
Board Members and Advisors 9
Employee Profiles
People
Sathvik Koneru
Software Engineer
People
Yuning Shen
High Throughput Chemist, Drug Discovery Scientist
People
Marco Falcioni
Senior Software Engineer
People
Terry Lou
Scientist

Unlock access to complete

Board Members and Advisors
people
Jorge Conde
Director
people
Mark Murcko
Director
people
George Petrocheilos
Director
people
Charles Zuker
Scientific Advisor

Unlock access to complete

Funding Insights of Octant

Octant has successfully raised a total of $110M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $80 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Series B — $80.0M
  • First Round

    (01 May 2020)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2022 Amount Series B - Octant Valuation Catalio Capital Management
Apr, 2021 Amount Grant - Octant Valuation

investors

HHS
May, 2020 Amount Series A - Octant Valuation a16z
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Octant

Octant has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Allen & Company and Bristol-Myers Squibb. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital is provided to biomedical technology startups.
Founded Year Domain Location
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
Founded Year Domain Location
Venture capital firm focused on multiple sectors
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Octant

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Octant

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Octant Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Octant

Octant operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DNAnexus, Arbor Biotechnologies, Cytel, Verge Genomics and Singleron, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Cloud-based genome informatics and data management are provided.
domain founded_year HQ Location
Genomic technologies and drug discovery platforms are provided.
domain founded_year HQ Location
Data analysis and statistical solutions are provided for life sciences.
domain founded_year HQ Location
Neurodegenerative disease drugs are developed using computational genomics.
domain founded_year HQ Location
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis
domain founded_year HQ Location
Next-generation gene editing tools are developed for drug enhancement.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Octant

Frequently Asked Questions about Octant

When was Octant founded?

Octant was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is Octant located?

Octant is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.

Is Octant a funded company?

Octant is a funded company, having raised a total of $110M across 4 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on May 01, 2020.

How many employees does Octant have?

As of Dec 31, 2024, the latest employee count at Octant is 63.

What does Octant do?

Octant is engaged in developing next-generation small molecule therapeutics by merging biology, chemistry, and computation. The company targets complex cellular mechanisms to address diseases caused by protein misfolding and mistrafficking. Solutions are built to deliver relief through innovative therapies, with a pipeline including treatments for retinitis pigmentosa, Fabry disease, and various cancers. Efforts are concentrated on precision medicine to transform drug discovery and clinical outcomes.

Who are the top competitors of Octant?

Octant's top competitors include DNAnexus, Arbor Biotechnologies and Cytel.

What products or services does Octant offer?

Octant offers OCT-980 and Genetic Disease Correctors.

Who are Octant's investors?

Octant has 8 investors. Key investors include HHS, Allen & Company, Bristol-Myers Squibb, Catalio Capital Management, and Andreessen Horowitz.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available